Team isolates stem cell that gives rise to bones, cartilage in mice

13 hours ago Hematopoietic precursor cells: promyelocyte in the center, two metamyelocytes next to it and band cells from a bone marrow aspirate. Credit: Bobjgalindo/Wikipedia

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

"Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn't heal well, but that lack of cartilage predisposes the patient to arthritis down the road," said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. "This research raises the possibility that we can create new skeletal stem cells from patients' own tissues and use them to grow new cartilage." Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stromathe spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

"Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells," said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

"If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another," said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Continued here:
Team isolates stem cell that gives rise to bones, cartilage in mice

Stem-cell therapy clinic to open in Valley

The new clinic claims its stem-cell treatment can benefit those suffering from emphysema, chronic bronchitis, pulmonary fibrosis and most forms of lung disease.(Photo: Getty Images/iStockphoto)

The Lung Institute, a national clinic that uses adult stem cells extracted from fat and blood to treat pulmonary conditions, is set to open next month in Scottsdale, the for-profit company's first location in the western United States.

The new clinic claims its treatment can benefit those suffering from emphysema, chronic bronchitis, pulmonary fibrosis and most forms of lung disease.

Such stem-cell therapy is part of a growing trend particularly among affluent Americans who can afford it to treat a variety of health problems with cells taken from their own bodies.

The industry remains largely controversial, with plenty of doubters and detractors who say the science is unproven and potentially dangerous.

The International Society for Stem Cell Research, an independent non-profit organization based in Illinois, cautions against the potential risk of some treatments, which it says could cause cancer or result in infection from the procedure itself. The group suggests patients speak with their doctor about the potential benefits or risks of stem-cell therapy.

For its part, Lung Institute says the treatment helps fight lung conditions including chronic obstructive pulmonary disease, one of the world's leading killers. Cells extracted from one organ can create healthy tissue in another organ, the company claims.

The therapy is provided as an outpatient service, and patients can have cells drawn, isolated and planted in the affected area all in the same day. The clinic does not use embryonic, umbilical cord or donor stem cells.

Lung Institute, a clinic that uses stem cells to treat pulmonary conditions, is set to open its first West Coast location in Scottsdale in February 2015.(Photo: Courtesy of Lung Institute)

Patients typically visit the clinic for a few hours over three consecutive days. The treatment seeks to slow disease progression, calm inflammation or repair damaged tissue.

See original here:
Stem-cell therapy clinic to open in Valley

Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

"Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn't heal well, but that lack of cartilage predisposes the patient to arthritis down the road," said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. "This research raises the possibility that we can create new skeletal stem cells from patients' own tissues and use them to grow new cartilage." Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stroma -- the spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

"Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells," said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

"If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another," said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Reprogramming fat cells

The rest is here:
Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

Bone stem cells shown to regenerate bones and cartilage in adult mice

IMAGE:The osteochondroretricular stem cell, a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis,... view more

Credit: Laboratory of Dr. Timothy Wang

NEW YORK, NY (January 15, 2015) - A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The discovery by researchers at Columbia University Medical Center (CUMC) is reported today in the online issue of the journal Cell.

The cells, called osteochondroreticular (OCR) stem cells, were discovered by tracking a protein expressed by the cells. Using this marker, the researchers found that OCR cells self-renew and generate key bone and cartilage cells, including osteoblasts and chondrocytes. Researchers also showed that OCR stem cells, when transplanted to a fracture site, contribute to bone repair.

"We are now trying to figure out whether we can persuade these cells to specifically regenerate after injury. If you make a fracture in the mouse, these cells will come alive again, generate both bone and cartilage in the mouse--and repair the fracture. The question is, could this happen in humans," says Siddhartha Mukherjee, MD, PhD, assistant professor of medicine at CUMC and a senior author of the study.

The researchers believe that OCR stem cells will be found in human bone tissue, as mice and humans have similar bone biology. Further study could provide greater understanding of how to prevent and treat osteoporosis, osteoarthritis, or bone fractures.

"Our findings raise the possibility that drugs or other therapies can be developed to stimulate the production of OCR stem cells and improve the body's ability to repair bone injury--a process that declines significantly in old age," says Timothy C. Wang, MD, the Dorothy L. and Daniel H. Silberberg Professor of Medicine at CUMC, who initiated this research. Previously, Dr. Wang found an analogous stem cell in the intestinal tract and observed that it was also abundant in the bone.

"These cells are particularly active during development, but they also increase in number in adulthood after bone injury," says Gerard Karsenty, MD, PhD, the Paul A. Marks Professor of Genetics and Development, chair of the Department of Genetics & Development, and a member of the research team.

The study also showed that the adult OCRs are distinct from mesenchymal stem cells (MSCs), which play a role in bone generation during development and adulthood. Researchers presumed that MSCs were the origin of all bone, cartilage, and fat, but recent studies have shown that these cells do not generate young bone and cartilage. The CUMC study suggests that OCR stem cells actually fill this function and that both OCR stems cells and MSCs contribute to bone maintenance and repair in adults.

The researchers also suspect that OCR cells may play a role in soft tissue cancers.

Continue reading here:
Bone stem cells shown to regenerate bones and cartilage in adult mice

Fallout from fake credentials

Winnipeg Free Press - PRINT EDITION

By: Mary Agnes Welch and Melissa Martin

Posted: 01/15/2015 3:00 AM | Comments:

The University of Winnipeg has axed a joint project with Regenetek Research, the local company selling stem-cell treatment to people with multiple sclerosis.

The move by the university's ethics committee came Wednesday, hours after the Free Press published its investigation into Regenetek owner Doug Broeska's credentials and his clinical trial.

The university's move puts an end to Broeska's repeated claim he was about to launch a study with U of W's kinesiology faculty to track and test some of the 70 patients who paid Regenetek as much as $45,000 for experimental stem-cell transplants in India.

"The patient outcomes have been so significant that we will soon be announcing a companion study with the University of Winnipeg," Broeska told a prospective patient in an email obtained by the Free Press. "Dr. Glen Bergeron, assistant dean and one of Canada's foremost physiotherapeutic specialists (head physiotherapist, Canadian Olympic Team) has confirmed our evidence based on patient observation... and would not have contemplated such a study if our patient/subjects had not demonstrated neural pathway restoration as a result of their therapies."

Winnipeg-based Regenetek and the U of W signed a preliminary letter of intent last spring. The company even gave the U of W $10,000 to hire a young researcher. She moved to Winnipeg from Waterloo, Ont., and began work in November in anticipation the joint research project would soon win ethics approval from the university's review panel.

Last week, the U of W's ethics committee sent the proposal back to Bergeron with questions and concerns. On Wednesday morning, the committee rejected the joint application outright.

Bergeron did not reply to requests for comment. Instead, Jino Distasio, the U of W's associate vice-president of research and innovation, said the university takes the health of study participants extremely seriously and already harboured concerns about the project.

Read the original:
Fallout from fake credentials

U of W cancels proposal for joint research study

Winnipeg Free Press - ONLINE EDITION

By: Melissa Martin and Mary Agnes Welch

Posted: 01/15/2015 2:00 AM | Comments:

The University of Winnipeg has axed a joint project with Regenetek Research, the local company selling stem-cell treatment to people with multiple sclerosis.

The move by the universitys ethics committee came Wednesday, hours after the Free Press published its investigation into Regenetek owner Doug Broeskas credentials and his clinical trial.

The universitys move puts an end to Broeskas repeated claim he was about to launch a study with U of Ws kinesiology faculty to track and test some of the 70 patients who paid Regenetek as much as $45,000 for experimental stem-cell transplants in India.

"The patient outcomes have been so significant that we will soon be announcing a companion study with the University of Winnipeg," Broeska told a prospective patient in an email obtained by the Free Press. "Dr. Glen Bergeron, assistant dean and one of Canadas foremost physiotherapeutic specialists (head physiotherapist, Canadian Olympic Team) has confirmed our evidence based on patient observation... and would not have contemplated such a study if our patient/subjects had not demonstrated neural pathway restoration as a result of their therapies."

Winnipeg-based Regenetek and the U of W signed a preliminary letter of intent last spring. The company even gave the U of W $10,000 to hire a young researcher. She moved to Winnipeg from Waterloo, Ont., and began work in November in anticipation the joint research project would soon win ethics approval from the universitys review panel.

Last week, the U of Ws ethics committee sent the proposal back to Bergeron with questions and concerns. On Wednesday morning, the committee rejected the joint application outright.

Bergeron did not reply to requests for comment. Instead, Jino Distasio, the U of Ws associate vice-president of research and innovation, said the university takes the health of study participants extremely seriously and already harboured concerns about the project.

Continued here:
U of W cancels proposal for joint research study

New test helps guide treatment for bone marrow transplant patients with graft vs. host disease

Innovative scoring system uses 'Ann Arbor GVHD score' to better predict how patients will respond, minimize side effects

ANN ARBOR, Mich. - A new test can guide treatment for patients with graft versus host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants, according to research from the University of Michigan published in Lancet Haematology this month.

Patients with fatal blood cancers like leukemia often need bone marrow or stem cell transplants to survive. But one of the most common and serious side effects that patients face is graft vs. host disease: when a patient's new immune system from the transplant (the graft) attacks the patient's healthy tissue (the host).

Most GVHD starts out as mild, but in two-thirds it eventually becomes severe. The treatment for severe GVHD is high doses of medications that knock out the immune system. But doctors have to be careful with drugs that further weaken a newly transplanted immune system, because they increase the risk for serious and life-threatening infections. Until now there has been no test to determine which cases of GVHD will become severe, so treatment is often delayed until the GVHD worsens.

The study's lead author, John Levine, M.D., of the University of Michigan's Blood and Marrow Transplant Program and his colleagues studied almost 800 patients from the US and Germany to develop and validate a new scoring system. The Ann Arbor GVHD score uses the levels of three proteins in the blood (TNFR1, ST2, and REG3a) to determine whether the patient should be treated right away or not and how intense the treatment should be. Patients with Ann Arbor 1 GVHD usually don't need treatment while patients with Ann Arbor 3 GVHD often don't respond to standard treatment and should be considered for clinical trials.

"We often have to treat all patients with GVHD alike with very high-dose steroids, because the severity of symptoms at the disease's onset don't help us predict how sick the patient will get. But this new scoring system will help identify patients that need a different approach, says Levine, who also is clinical director of the Pediatric Blood and Marrow Transplantation program at C.S. Mott Children's Hospital.

"And it can help us with patients with lower-risk GVHD who we may be over-treating. These scores can help us find a better, more individualized fit for our patients as soon as their disease is diagnosed," says Levine, who is professor of pediatrics at the University of Michigan Medical School.

Around half of patients who get a bone marrow transplant will develop GVHD, which can be lethal if it can't be controlled.

"Our goal is to offer personalized care. Doctors have struggled with individualizing therapy for each patient, but there's been no new therapy for GVHD in more than 40 years. So this new scoring system gives us another tool to better take care of our patients," Levine says.

###

Read more from the original source:
New test helps guide treatment for bone marrow transplant patients with graft vs. host disease

New device allows for manipulation of differentiating stem cells

Electroporation is a powerful technique in molecular biology. By using an electrical pulse to create a temporary nanopore in a cell membrane, researchers can deliver chemicals, drugs, and DNA directly into a single cell.

But existing electroporation methods require high electric field strengths and for cells to be suspended in solution, which disrupts cellular pathways and creates a harsh environment for sensitive primary cells. This makes it nearly impossible for researchers to study the cells naturally, in a setting that encourages the cells to continue differentiating and expanding.

A Northwestern University collaboration has developed a novel microfluidic device that allows for electroporation of stem cells during differentiation, making it possible to deliver molecules during this pivotal time in a cell's life. This provides the conditions needed to study primary cells, such as neurons, opening doors for exploration of the pathogenic mechanisms of neural diseases and potentially leading to new gene therapies.

Developed by Horacio Espinosa, the James and Nancy Farley Professor of Manufacturing and Entrepreneurship at the McCormick School of Engineering, and John Kessler, the Ken and Ruth Davee Professor of Stem Cell Biology at the Feinberg School of Medicine, the localized electroporation device (LEPD) can be applied to adherent cells, which are grown on an artificial substrate as opposed to free-floating in a culture medium and are able to continue growing and differentiating.

"The ability to deliver molecules into adherent cells without disrupting differentiation is needed for biotechnology researchers to advance both fundamental knowledge and the state-of-the-art in stem cell research," Espinosa said.

"Non-destructive manipulation of cells over time and in the correct environment is a key enabling technology highly needed within the biology and medical research communities," Kessler said.

###

Supported by the National Science Foundation and the National Institutes of Health, the research is described in a paper published in the September 10 issue of Lab on a Chip, the journal of The Royal Society of Chemistry, and was also highlighted on the journal's back cover. Other authors on the paper include Wonmo Kang, Juan P. Giraldo-Vela, Shiva Nathamgari, Tammy McGuire, and Rebecca McNaughton.

The team fabricated the LEPD by employing a commonly used polymer for rapid prototyping of microfluidic devices for biological applications. It consists of circulation microchannels beneath a cell culture chamber made up of a perforated substrate and built-in electrodes. Although the main applications of the initial research examined neurons, the device is a general tool that can be used for any type of adherent cell.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the article here:
New device allows for manipulation of differentiating stem cells

New Approach, New Hope: $12M New York State Investment Will Fast-Track Innovative Roswell Park Research in Ovarian …

Buffalo, NY (PRWEB) January 14, 2015

Researchers at Roswell Park Cancer Institute (RPCI) have received a prestigious grant of nearly $12 million from the New York State Stem Cell Science Program (NYSTEM) to develop new therapies for advanced ovarian cancer. The four-year, $11.9 million grant to RPCI is one of three new state awards totaling $36 million to support innovative approaches for developing stem-cell based therapies for diseases that are notoriously hard to treat. The clinical need for new treatments is dire, as advanced ovarian cancer is an aggressive and typically fatal disease.

Using an approach known as adoptive T-cell therapy, the Roswell Park team, led by Kunle Odunsi, MD, PhD, FRCOG, FACOG, Chair of the Department of Gynecologic Oncology, M. Steven Piver Professor of Gynecologic Oncology and Executive Director of the Center for Immunotherapy, will take stem cells from patients blood, re-engineer them and infuse the reprogrammed cells back into those patients. Once inside the patients body, the re-engineered stem cells become a continuous, potentially lifelong source of cancer-fighting immune cells. This strategy has proven successful in preclinical studies as a way to not only eradicate existing cancer but to prevent new cancer cells from developing.

New York is home to some of the best researchers across the globe, and this funding will help ensure they can do the necessary work to grow our progress in stem cell science, New York Governor Andrew M. Cuomo said in announcing the awards on Jan. 12. This state is proud to be a leader in the health industry, and with this funding we will continue to develop modern, world-class research programs that work to make people worldwide healthier.

The concept behind this new and novel project, which builds on past Roswell Park research, is to unite the cancer-killing power of T cells with the long-term regenerative power of adult stem cells. By enlisting both killer CD8+ T cells and helper CD4+ T cells, the researchers will be able to turn a patients own, reprogrammed stem cells into immune cells armed with the ability to recognize and kill cancer cells.

This project represents a potentially paradigm-shifting approach in the use of immunotherapy to treat cancer, because we will be generating billions of these antitumor effector cells to continually control existing tumors and minimize the chance of relapse, said Dr. Odunsi, who is also Co-Leader of Roswell Parks Tumor Immunology and Immunotherapy Program and a Professor of Gynecology & Obstetrics at the University at Buffalo (UB). Reprograming adult hematopoietic stem cells for sustained attack against ovarian cancer is, to our knowledge, a completely new approach.

Like much previous RPCI research on immune therapies to combat ovarian cancer, this new project targets the NY-ESO-1 antigen, which is expressed in cancer cells but not in most normal body tissues. Because this protein is so widely expressed by various malignant tumors, the approach may have application in the treatment of other cancers as well.

The project will encompass both preclinical work and an early-phase clinical research study in patients with ovarian cancer, and will take advantage of three resources housed within the RPCI Center for Immunotherapy:

Roswell Park faculty members Thinle Chodon, MD, PhD, and Takemasa Tsuji, PhD, are also among Dr. Odunsis co-investigators, as are Dr. Richard Bankert, VMD, PhD, from the Department of Microbiology and Immunology at the University at Buffalo and Leonard Shultz, PhD, from The Jackson Laboratory, Bar Harbor, Maine.

This Roswell Park-developed, Roswell Park-led initiative is just the latest example of the ingenuity Dr. Odunsi and his team bring to the pressing challenge of how to develop better and more effective therapies for cancer, said Candace Johnson, PhD, President & CEO and Cancer Center Director at Roswell Park. We are enormously grateful for the leadership Gov. Cuomo and NYSTEM have shown in dedicating these funds strategically to address high-priority medical issues, and to the numerous individual and corporate donors whose contributions to the Roswell Park Alliance Foundation enabled the laboratory advances that Dr. Odunsi and his team will now be able to bring to patients.

Here is the original post:
New Approach, New Hope: $12M New York State Investment Will Fast-Track Innovative Roswell Park Research in Ovarian ...